Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAP-CAP Influenza Antiviral Domain
jRCTs051240171Recruiting
- Sponsor
- Japan Science and Technology Agency
- Start
- Dec 2024
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of oseltamivir and baloxavir marboxil in influenza (5 arms), sponsored by Japan Science and Technology Agency. Primary endpoints: Landmark mortality at Day 90 post randomization and Respiratory support level among Day 90 survivors. Started Dec 2024; status: recruiting.
02
Drugs
oseltamivirbaloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on jRCTs051240171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240171.